Reproductive Embryo Editing: Attending to Justice
By Inmaculada De Melo-Martín,
The Hastings Center Report
| 08. 22. 2022
Advances in genome editing technologies allow scientists to add, remove, or alter genetic material at particular locations in the human genome. Genome editing of somatic cells offers great promise in the prevention and treatment of various human diseases. But these technologies could also be used to modify gametes and embryos. Some commentators defend gene editing for reproductive purposes on the ground that it would allow people who are at risk of transmitting genetic diseases to their offspring to have healthy and genetically related children.
Using gene editing in this way would require further research. The technology still presents problems involving off-target effects and reliability. Researchers must improve delivery to desired tissues and control of immunogenic reactions. Yet I argue here that, if we accept certain background claims about justice, accepting the goal of helping people have healthy and genetically related children should commit one to rejecting the investment of social resources into further development of reproductive embryo editing.
Considerations of justice are relevant to questions regarding the development of reproductive embryo editing for several reasons. First, decisions about research-funding priorities involve...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...